What is the impact of adopting SFAS No. 123 on Regeneron's financial reporting?

Effective January 1, 2005, Regeneron began recognizing non-cash compensation expense for employee stock option awards in its operating expenses. This means that prior to this date, these costs were not reflected in operating results, and past periods have not been restated. The company is providing non-GAAP measures that exclude this expense to aid in comparison and understanding.

What is the significance of the non-GAAP financial measures reported?

Regeneron's management believes that presenting non-GAAP financial measures, such as pro forma net income and pro forma expenses (exclusive of stock option expense), provides investors with a clearer view of the company's operating trends and results. These measures are intended to offer greater transparency and a more useful basis for comparing performance, especially as they remove the impact of the newly recognized stock option expense.

What is the status of the securities class action lawsuit?

Regeneron has entered into a settlement agreement to resolve all claims in the securities class action lawsuit. Crucially, Regeneron and its individual defendants will not incur any payment; the settlement will be covered by the company's primary insurance carrier at an immaterial cost to Regeneron. The settlement includes no admission of wrongdoing and is subject to final court approval.

Does the settlement of the securities litigation involve any admission of fault by Regeneron?

No, the settlement explicitly states that it includes no admission of wrongdoing by Regeneron or any of the individual defendants named in the lawsuit. This is a key aspect of the agreement, providing closure without acknowledging any liability.

REGN 8-K: Earnings & Results

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 4, 2005, announcing its financial and operating results for the quarter and six months ended June 30, 2005. A key development reported is the adoption of SFAS No. 123, requiring the recognition of non-cash compensation expense for employee stock options starting January 1, 2005. The company has provided non-GAAP financial measures, such as pro forma net income and expenses, which exclude this stock option expense to offer greater transparency and comparability. These non-GAAP figures are presented alongside GAAP results, with reconciliations provided. Furthermore, the filing details a significant legal development: Regeneron has entered into a Stipulation and Agreement of Settlement to resolve all claims in the securities class action lawsuit, In re Regeneron Pharmaceuticals, Inc. Securities Litigation. Importantly, this settlement requires no payment from Regeneron or its individual defendants; the company's primary insurance carrier will cover an immaterial amount. The settlement includes no admission of wrongdoing and is subject to court approval. This resolution brings closure to a significant legal overhang for the company.

Key Highlights

1Regeneron announced its financial and operating results for Q2 and H1 2005.
2The company adopted SFAS No. 123, requiring the expensing of employee stock options starting January 1, 2005.
3Regeneron is presenting non-GAAP financial measures (pro forma net income, expenses) that exclude stock option expense for enhanced transparency and comparability.
4These non-GAAP measures are reconciled to GAAP figures in the accompanying press release.
5Regeneron has reached a settlement for the securities class action lawsuit (In re Regeneron Pharmaceuticals, Inc. Securities Litigation).
6The settlement requires no financial contribution from Regeneron or its individual defendants; insurance will cover an immaterial amount.
7The settlement includes no admission of wrongdoing by Regeneron or its executives.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Aug 4, 2005)

Summary

Key Highlights

Frequently Asked Questions